Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P McGettigan

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Australian Family Physician|September 29, 2000
COX-2 inhibitors. What is their place?P McGettigan
Expert Review of Vaccines|October 7, 2010
Experimental rabies vaccines for humansJames P McGettigan
Current Pharmaceutical Design|December 5, 2000
Current problems with non-specific COX inhibitorsP McGettigan, D Henry
Inflammopharmacology|July 20, 2007
Cardiac and renal failure due to NSAIDs: a review of the epidemiological literatureD Henry, P McGettigan
British Journal of Clinical Pharmacology|January 3, 2001
Quality use of medicines in the community: the Australian experienceA J Smith, P McGettigan
British Journal of Clinical Pharmacology|April 1, 1997
Hospital antibiotic prescribing and feedbackL Hemeryck, P McGettigan, J Feely
Clinical Pharmacology and Therapeutics|May 9, 2000
Growth in use of statins after trials is not targeted to most appropriate patientsJ Feely, P McGettigan, A Kelly
Plos Neglected Tropical Diseases|November 15, 2019
Incorporating B cell activating factor (BAFF) into the membrane of rabies virus (RABV) particles improves the speed and magnitude of vaccine-induced antibody responsesJoseph R Plummer, James P McGettigan
Journal of Analytical Toxicology|January 5, 2002
A fatal case of moclobemide-citalopram intoxicationG K Isbister, P McGettigan, A Dawson
Pharmacoepidemiology and Drug Safety|November 26, 2008
Anti-depressants in primary care: analysis of treatment discontinuationsP McGettigan, A Kelly, M Carvahlo, et al.
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Australian Family Physician|September 29, 2000
COX-2 inhibitors. What is their place?P McGettigan
Expert Review of Vaccines|October 7, 2010
Experimental rabies vaccines for humansJames P McGettigan
Current Pharmaceutical Design|December 5, 2000
Current problems with non-specific COX inhibitorsP McGettigan, D Henry
Inflammopharmacology|July 20, 2007
Cardiac and renal failure due to NSAIDs: a review of the epidemiological literatureD Henry, P McGettigan
British Journal of Clinical Pharmacology|January 3, 2001
Quality use of medicines in the community: the Australian experienceA J Smith, P McGettigan
British Journal of Clinical Pharmacology|April 1, 1997
Hospital antibiotic prescribing and feedbackL Hemeryck, P McGettigan, J Feely
Clinical Pharmacology and Therapeutics|May 9, 2000
Growth in use of statins after trials is not targeted to most appropriate patientsJ Feely, P McGettigan, A Kelly
Plos Neglected Tropical Diseases|November 15, 2019
Incorporating B cell activating factor (BAFF) into the membrane of rabies virus (RABV) particles improves the speed and magnitude of vaccine-induced antibody responsesJoseph R Plummer, James P McGettigan
Journal of Analytical Toxicology|January 5, 2002
A fatal case of moclobemide-citalopram intoxicationG K Isbister, P McGettigan, A Dawson
Pharmacoepidemiology and Drug Safety|November 26, 2008
Anti-depressants in primary care: analysis of treatment discontinuationsP McGettigan, A Kelly, M Carvahlo, et al.
Pageof 7